EUDA Health Holdings Limited (NASDAQ:EUDA) a Singapore-based distributor of third-party provided wellness and non-invasive healthcare products and services in Asia, with a focus on Singapore, Malaysia and China, today provided important additional details of the integrated cell therapy program to be pursued under its recently announced non-binding Memorandum of Understanding (MOU) with GO POSB Organoids Pte Ltd ("GO POSB") and Shenzhen Innovation Immunotechnology Co., Ltd. ("SIIT").

Subject to the execution of definitive agreements and applicable regulatory approvals, parties plan to combine GO POSB’s proprietary induced pluripotent stem cell ("iPSC") platform and clinical-grade universal tumor organoid bank with SIIT’s Natural Killer ("NK") and NK-TCR cell engineering capabilities and GMP manufacturing expertise to explore for the future development, manufacturing and commercialization of a new generation of off-the-shelf cell therapies for both wellness and oncology applications.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.